Search Results for "Pradaxa Atrial Septal Defect"
Original Source: Dabigatran in atrial fibrillation: pharmacology and clinical trials.
The central pharmacologic approach to stroke prevention in atrial fibrillation has recently changed with the approval of dabigatran by the US Food and Drug Administration (FDA). Dabigatran is an oral anticoagulant that belongs to the class of direct thrombin inhibitors. Dabigatran has predictable pharmacokinetics, without significant drug and food interactions, rapid onset, and requires twice-daily administration without the need for monitoring. The only drug contraindicated with dabigatran is rifampin. In...
Matching Channels
Matching News
Focus on Safety and Effectiveness of GORE@ HELEX@ Septal Occluder for Closure of Atrial Septal Defect (ASD) FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Jun 7, 2012-- W. L. Gore & Associates (Gore) todaya...
Gore enrolls first patient in Septal Occluder clinical trial
W. L. Gore & Associates has completed enrolling first patient in a clinical trial of its GORE Septal Occluder, designed for the percutaneous, trancatheter closure of ostium secundum atrial septal defe...
FDA To Reassess Heart Defect Closure Devices Given New Safety Data
An advisory panel today will consider implications of post-market adverse event rates associated with atrial septal defect occluders made by St. Jude Medical and W.L.
Heart Defect Closure Rate Increasing (CME/CE)
ORLANDO (MedPage Today) -- The number of procedures performed to close an atrial septal defect or patent foramen ovale has increased in recent years, while length of stay associated with the procedure...
Defer closure of atrial septal defects in small children: study
NEW YORK (Reuters Health) - Elective closure of asymptomatic secundum atrial septal defects (ASD) in children who weigh less than 15 kg can be safely deferred until the child is older and larger,...
FDA Panel Recommends New Studies of ASD Occluders
In response to reports of erosions, fractures, and embolizations of atrial septal defect occlusion devices, the FDA Circulatory System Devices Advisory Committee had a long and wide-ranging discussion...
Pradaxa efficacy and cost effectiveness advantages over Xarelto
Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's Pradaxa; dabigatran etexilate) and the Rocket AF trial (for German major Bayer's BAYN: DE Xarelto;...
Analysis Gives Edge to Pradaxa Over Xarelto (CME/CE)
(MedPage Today) -- The highest approved dose of dabigatran (Pradaxa) was better at reducing the risk of stroke or systemic embolism in patients with atrial fibrillation than rivaroxaban (Xarelto), an...
Matching PubMed Articles
Mixed atrial septal defect coexisting ostium secundum and sinus venosus atrial septal defect.
Treatment of prosthetic patch endocarditis after closure of a ventricular septal defect is challenging. It is essential to reduce inflammation and prevent recurrence of endocarditis. We report a succe...
The presence of an atrial septal defect in pulmonary hypertension has benefits and detractions. Even in idiopathic pulmonary arterial hypertension, a significant left-to-right shunt at atrial level ma...
Abstract Although wire device frame fracture associated with thrombus formation has been reported in some types of atrial septal defect occluders, it has not been detected in patients with Amplatzer d...
Bicuspid pulmonary valve with atrial septal defect leading to pulmonary aneurysm.
Pulmonary artery aneurysms are rare. We describe 2 adult patients with pulmonary artery aneurysm with normal pulmonary pressure associated with bicuspid pulmonary valve and atrial septal defect. One p...
